A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.

Koblan, Kenneth S; Kent, Justine; Hopkins, Seth C; Krystal, John H; Cheng, Hailong; Goldman, Robert; Loebel, Antony

Koblan, Kenneth S; Kent, Justine; Hopkins, Seth C; Krystal, John H; Cheng, Hailong; Goldman, Robert; Loebel, Antony.

Affiliation

Koblan KS; From Sunovion Pharmaceuticals, Marlborough, MA (K.S.K., J.K., S.C.H., H.C., R.G., A.L.); and the Department of Psychiatry, Yale University, the Department of Neuroscience, Yale University School of Medicine, and Behavioral Health Services, Yale New Haven Hospital, New Haven (J.H.K.), and the Clinica
Kent J; From Sunovion Pharmaceuticals, Marlborough, MA (K.S.K., J.K., S.C.H., H.C., R.G., A.L.); and the Department of Psychiatry, Yale University, the Department of Neuroscience, Yale University School of Medicine, and Behavioral Health Services, Yale New Haven Hospital, New Haven (J.H.K.), and the Clinica
Hopkins SC; From Sunovion Pharmaceuticals, Marlborough, MA (K.S.K., J.K., S.C.H., H.C., R.G., A.L.); and the Department of Psychiatry, Yale University, the Department of Neuroscience, Yale University School of Medicine, and Behavioral Health Services, Yale New Haven Hospital, New Haven (J.H.K.), and the Clinica
Krystal JH; From Sunovion Pharmaceuticals, Marlborough, MA (K.S.K., J.K., S.C.H., H.C., R.G., A.L.); and the Department of Psychiatry, Yale University, the Department of Neuroscience, Yale University School of Medicine, and Behavioral Health Services, Yale New Haven Hospital, New Haven (J.H.K.), and the Clinica
Cheng H; From Sunovion Pharmaceuticals, Marlborough, MA (K.S.K., J.K., S.C.H., H.C., R.G., A.L.); and the Department of Psychiatry, Yale University, the Department of Neuroscience, Yale University School of Medicine, and Behavioral Health Services, Yale New Haven Hospital, New Haven (J.H.K.), and the Clinica
Goldman R; From Sunovion Pharmaceuticals, Marlborough, MA (K.S.K., J.K., S.C.H., H.C., R.G., A.L.); and the Department of Psychiatry, Yale University, the Department of Neuroscience, Yale University School of Medicine, and Behavioral Health Services, Yale New Haven Hospital, New Haven (J.H.K.), and the Clinica
Loebel A; From Sunovion Pharmaceuticals, Marlborough, MA (K.S.K., J.K., S.C.H., H.C., R.G., A.L.); and the Department of Psychiatry, Yale University, the Department of Neuroscience, Yale University School of Medicine, and Behavioral Health Services, Yale New Haven Hospital, New Haven (J.H.K.), and the Clinica

N Engl J Med ; 382(16): 1497-1506, 2020 04 16.

Article de En | MEDLINE | ID: mdl-32294346

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Schizophrénie / Neuroleptiques Type d'étude: Clinical_trials Limites: Adult / Female / Humans / Male Langue: En Journal: N Engl J Med Année: 2020 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google